Table 4 Analysis of the relationship between pre-chemotherapy patient-related factors and maintenance of usual daily food intake in the overall phase (day 1 to 5).

From: Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)

Variables

Subgroup

No. of patients

NEPA + DEX1 (n = 76)

No. of patients

NEPA + DEX4 (n = 76)

OR (95% CI)

p-value*

Usual daily food intake

Usual daily food intake

N

%

N

%

Age

 ≥ 55 years

69

48

69.6

66

48

72.7

1.04

0.83

 < 55 years

7

5

71.4

10

7

70

(0.34; 3.15)

Sex

Female

21

15

71.4

22

14

63.6

0.79

0.67

Male

55

38

69.1

54

41

75.9

(0.37; 1.68)

Alcohol intake

No

55

41

74.5

50

36

72

1.43

0.45

Everyday

21

12

57.1

26

19

73.1

(0.68; 3.0)

ECOG PS score

0

63

42

66.7

58

43

74.1

0.83

0.86

1

13

11

84.6

18

12

66.7

(0.34; 2.03)

Tumor stage

Early

20

15

75

16

10

62.5

0.91

0.99

Advanced

56

38

67.9

60

45

75

(0.41; 2.05)

Food intake**

More than usual or Unchanged

55

38

69.1

53

42

79.2

1.63

0.27

Less than usual

21

15

71.4

23

13

56.5

(0.77; 3.43)

BMI-adjusted

0–1

52

35

67.3

47

37

78.7

1.27

0.65

WL grade***

2–4

24

18

75

29

18

62.1

(0.61; 2.62)

  1. NEPA fixed combination of netupitant and palonosetron, DEX1 dexamethasone day 1, DEX4 dexamethasone day 1 to 4, OR odds ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, BMI body mass index, WL weight loss.
  2. *p-value was calculated using the Mantel–Haenszel chi-square test (two-tailed) stratified by treatment group.
  3. **As compared with their normal food intake, patients self-reported food intake during the past month before the study entry.
  4. ***Increasing WL grades are associated with reduced quality of life and reduced survival.
Back to article page